Drug helps acute myeloid leukemia patients
Posted on: Wednesday, 17 December 2008, 13:07 CST
A French-led international study suggests acute myeloid leukemia patients treated with Vidaza (azacitidine) have significantly increased overall survival.
Acute myeloid leukemia is a cancer in which abnormal cells accumulate in bone marrow and interfere with normal blood cell production. Patients with AML typically have a poor prognosis and do not respond well to conventional chemotherapy, researchers said, noting approximately 30 percent of patients diagnosed with myelodysplastic syndrome, formerly known as preleukemia,
will progress to AML.
Dr. Pierre Fenaux of the University of Paris said the results from an international phase III trial that was the first to show an increased overall survival for higher-risk MDS patients. The study showed 50 percent of the AML patients who were treated with Vidaza survived at least two years, compared with only 16 percent of patients treated with conventional regimens.
The data … are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years,
said Kathy Heptinstall, operating director of the Myelodysplastic Syndromes Foundation, We are hopeful about the potential of novel therapies, like Vidaza, which are helping patients to live longer with a better quality of life.
The study data were presented last week in San Francisco during the annual meeting of the American Society of Hematology.
Source: United Press International
Related Articles
- Regeneron's ARCALYST(R) (Rilonacept) Reduced Incidence of Gout Flares By 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
- XTL Completes Patient Randomization in Phase IIb Study of Diabetic Pain Drug
- Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
- Merck's Investigational Rolofylline Associated With Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study
- Last Patient Enrolled In ATryn(R) Pivotal Study
- MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent With Seven-Day Schedule
- Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes...
- VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates As High As 54 Percent in Patients With Previously Treated Multiple Myeloma
- Javelin Treats First Patient in Phase III Pain Study
- Patient Deaths Decline in Early Studies of New Cancer Drugs More-Targeted Drugs, More Emphasis on Patient Safety Cited in Minimizing Risk
 |
 |
User Comments (0)
RSS Feeds